GeneNews (GEN) Stock Price, News & Analysis

Company Overview

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$0.15 to C$0.15
• 52-Week Range: N/A
• Volume: 473,147 shs
• Average Volume: 1.48 million shs
• Market Capitalization: C$25.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GEN Stock Analysis - Frequently Asked Questions

How do I buy shares of GeneNews?

Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of GeneNews own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneNews investors own include MARA (MARA), Ocugen (OCGN), Spero Therapeutics (SPRO), StorageVault Canada (SVI), American Airlines Group (AAL), First Majestic Silver (AG) and Antibe Therapeutics (ATE).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Computer Software
• Current Symbol: TSE:GEN
• CUSIP: N/A
• CIK: N/A
• Web: www.genenews.com
• Phone: +1-905-7392030
• Fax: N/A
• Employees: 2,700
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.10
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: C$234,592.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 145.00
• Book Value: C($0.06) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 169,963,000
• Free Float: N/A
• Market Cap: C$25.49 million
• Optionable: Not Optionable
• Beta: N/A